Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07236034

ARISe at UMass Chan

The goal is to identify the most impactful strategies for capturing attention and enhancing effectiveness of vaccine promotion messages. This will be done using an online survey that employs remote eye-tracking and self report measures to evaluate response to sample vaccine promotion social media content in rural populations in New England. Participants will be randomly assigned into one of 14 conditions in a 2(source: expert vs. influencer) by 7 (themes: constructs from 7C Vaccine Framework) experiment and view sample messages and then answer questions about their attitudes and beliefs while being monitored for eye-tracking.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Massachusetts Chan Medical School

Worcester, Massachusetts, 01605, United States

Location status: Recruiting

Location contact

Grace Assistant Professor, PhD, MPH

CONTACT

[email protected]

508-859-0179

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18+
  • Living in New England state (CT, MA, ME, NH, VT RI) in a zip code as defined by each individual state's definition of rural
  • Able to read and write in English
  • Access to an internet connected computer or laptop with a web-camera

Exclusion criteria

  • N/A

Treatment and study plan

Exposure to source and message content

Behavioral

Within each arm, participants will be exposed to two messages each of which are delivered by the same source (peer or professional) and have message content related to one of the 7C Constructs.

Primary outcomes

  1. Source credibility

    Time frame: Immediately after viewing each message

    Participants' perception of the credibility of the message source will be assessed using a 7-point Likert scale measured across four items. Participants will be asked to rate the following four items on this scale: To what extent do you believe the source of the message to be… (1=not at all, 7=very much so)

    • Fair
    • Accurate
    • Telling the whole story
    • Trustworthy

    Unit of measure: Scale score 1-7, mean

  2. Perceived Message Effectiveness

    Time frame: Immediately after viewing each message

    Perceived message effectiveness will be measured using six items (worth remembering, grabs attention, powerful, informative, meaningful, convincing), each rated on a 7-point Likert scale. The outcome will be the mean of these six ratings for each participant, then averaged by experimental condition.

    To what extent is… (1=not at all, 7=very much so)

    • The message worth remembering
    • The message grabs attention
    • This message powerful
    • This message informative
    • This message meaningful
    • This message convincing Unit of Measure: Scale score (1-7, mean across items)
  3. Visual attention

    Time frame: During message viewing ( immediately post-randomization, prior to completion of post-message survey)

    Visual attention, quantified as mean dwell time in milliseconds, will be measured using remote eye-tracking while participants view vaccine promotion messages. Dwell time will be calculated for pre-specified Areas of Interest (AOIs) during the message viewing period. Higher dwell times indicate greater visual attention to the AOIs.

    Unit of measure: mean dwell time in milliseconds per message

  4. Message reactance

    Time frame: Immediately after viewing each message

    Reactance will be assessed using four items (irritated, angry, annoyed, aggravated), rated 0 ("None of this feeling") to 4 ("A great deal of this feeling"). The mean reactance score will be calculated for each participant.

    How much did this message make you feel the following way? Response options: 0 (None of this feeling) to 4 (A great deal of this feeling).

    • Irritated
    • Angry
    • Annoyed
    • Aggravated

    Unit of Measure: Scale score (0-4, mean across items)

  5. Information sharing intentions

    Time frame: Immediately after viewing each message

    Description: Assessed with 6 items regarding interpersonal and online sharing, rated 1 (Strongly disagree) to 5 (Strongly agree). The mean score across items will be reported per participant and per condition.

    Rate with the following statements on a scale from 1 (Strongly disagree) to 5 (Strongly agree).

    Interpersonal setting

    • I would be willing to share this information with others.
    • I would talk with others about this message.
    • I would point others in a direction where they could read this message.

    Online setting

    • I would be willing to post a link to this information on my social media.
    • I would like a social media post with this information.
    • I would share a social media post with this information.

    Unit of Measure: Scale score (1-5, mean across items)

Secondary outcomes

  1. Vaccine perceptions

    Time frame: Assessed at baseline (prior to message exposure) and immediately post-intervention (after message exposure)

    Vaccine perceptions will be measured using an 8-item scale, administered pre- and post-message exposure. Items are rated from 1 (Strongly disagree/very negative) to 7 (Strongly agree/very positive). Higher scores indicate more positive vaccine perceptions. The outcome will be the mean change in score from pre- to post-exposure.

    Unit of Measure: Scale score (1-7, mean change)

Study contacts

Contact information is provided by the study sponsor or research team.

Grace W Ryan, PhD, MPH

CONTACT

[email protected]

508-859-0179

Sponsors and collaborators

Lead sponsor

University of Massachusetts, Worcester

Other

Registry information

Official study title

ARISe at UMass Chan: Remote Eye Tracking Study of Vaccine Messaging in Rural Populations

Acronym: ARISe

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 19, 2025
Registry last updated
Jul 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.